Published in Naunyn Schmiedebergs Arch Pharmacol on March 26, 2010
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J Exp Med (2012) 1.11
Allosteric modulation of glycine receptors. Br J Pharmacol (2011) 1.01
Mutations at beta N265 in γ-aminobutyric acid type A receptors alter both binding affinity and efficacy of potent anesthetics. PLoS One (2014) 0.94
Molecular sites for the positive allosteric modulation of glycine receptors by endocannabinoids. PLoS One (2011) 0.90
A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors. J Neurosci (2012) 0.86
Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod (2017) 0.75
Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch (1981) 134.60
Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A (1985) 68.48
Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature (1997) 7.49
Molecular structure and physiological function of chloride channels. Physiol Rev (2002) 6.09
Cannabidiol--recent advances. Chem Biodivers (2007) 2.89
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid. Proc Natl Acad Sci U S A (1997) 2.73
The beta subunit determines the ligand binding properties of synaptic glycine receptors. Neuron (2005) 2.42
Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature (2008) 2.30
Liquid filament switch for ultra-fast exchanges of solutions at excised patches of synaptic membrane of crayfish muscle. Neurosci Lett (1987) 2.13
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
Glycine receptors: recent insights into their structural organization and functional diversity. J Neurochem (2006) 1.61
The glycinergic control of spinal pain processing. Cell Mol Life Sci (2005) 1.52
Colocalization of GABA, glycine, and their receptors at synapses in the rat spinal cord. J Neurosci (1996) 1.49
Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses? Trends Pharmacol Sci (2002) 1.31
Mechanisms of pain modulation in chronic syndromes. Neurology (2002) 1.13
Glycine receptors: a new therapeutic target in pain pathways. Curr Opin Investig Drugs (2006) 1.07
Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol (2005) 1.07
Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain (2005) 1.00
Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol Pharmacol (1999) 0.99
Trichloroethanol modulation of recombinant GABAA, glycine and GABA rho 1 receptors. J Pharmacol Exp Ther (1998) 0.98
The interaction of anaesthetic steroids with recombinant glycine and GABAA receptors. Br J Anaesth (2004) 0.97
Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs (2007) 0.96
Glycine and GABA(A) receptor subunits on Renshaw cells: relationship with presynaptic neurotransmitters and postsynaptic gephyrin clusters. J Comp Neurol (2002) 0.95
The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-Beta glycine receptor function. Pharmacology (2009) 0.90
On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem Biodivers (2007) 0.87
A transmembrane residue influences the interaction of propofol with the strychnine-sensitive glycine alpha1 and alpha1beta receptor. Anesth Analg (2008) 0.85
Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sci (2004) 0.83
Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J (2005) 0.82
The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther (2007) 0.81
2,6 di-tert-butylphenol, a nonanesthetic propofol analog, modulates alpha1beta glycine receptor function in a manner distinct from propofol. Anesth Analg (2004) 0.81
Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine alpha1- and alpha1beta-receptors. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.78
Structural features of phenol derivatives determining potency for activation of chloride currents via alpha(1) homomeric and alpha(1)beta heteromeric glycine receptors. Br J Pharmacol (2005) 0.77
[The synthetic cannabinoid analog WIN 55,212-2 potentiates the amplitudes of glycine-activated currents]. Fiziol Zh (2007) 0.75
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol (2007) 3.96
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol (2009) 1.56
Endotoxin reduces availability of voltage-gated human skeletal muscle sodium channels at depolarized membrane potentials. Crit Care Med (2008) 1.51
Triple stimulation technique (TST) in amyotrophic lateral sclerosis. Clin Neurophysiol (2004) 1.47
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47
Adjuvant auricular electroacupuncture and autogenic training in rheumatoid arthritis: a randomized controlled trial. Auricular acupuncture and autogenic training in rheumatoid arthritis. Forsch Komplementmed (2008) 1.44
Prefrontal and anterior cingulate cortex abnormalities in Tourette Syndrome: evidence from voxel-based morphometry and magnetization transfer imaging. BMC Neurosci (2009) 1.26
ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci (2008) 1.22
Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis. BMC Neurol (2006) 1.21
Contrast extravasation on computed tomography angiography predicts clinical outcome in primary intracerebral hemorrhage: a prospective study of 139 cases. Stroke (2011) 1.18
Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol (2008) 1.17
Fatal outcome in a child after ingestion of a transdermal fentanyl patch. Int J Legal Med (2006) 1.11
Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol (2009) 1.10
Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal (2012) 1.10
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One (2012) 1.09
Distribution of GABAA receptor mRNA in the motor cortex of ALS patients. J Neuropathol Exp Neurol (2003) 1.08
Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): a possible mechanism of metabolic neuropathies. J Biol Chem (2012) 1.06
Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 1.05
Repetitive transcranial magnetic stimulation for the treatment of chronic pain - a pilot study. Eur Neurol (2002) 1.03
Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler (2007) 1.01
Kinetic properties of human AMPA-type glutamate receptors expressed in HEK293 cells. Eur J Neurosci (2003) 1.01
Increased intracortical inhibition in middle-aged humans; a study using paired-pulse transcranial magnetic stimulation. Neurosci Lett (2002) 1.01
Functional neuroimaging at different disease stages reveals distinct phases of neuroplastic changes in amyotrophic lateral sclerosis. Hum Brain Mapp (2011) 1.01
Blood volume measurements using an integrated fiberoptic monitoring system in a porcine septic shock model. Crit Care Med (2006) 1.00
Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). Behav Brain Res (2010) 1.00
Sustained effects of comprehensive inpatient rehabilitative treatment and sleeping neck support in patients with chronic cervicobrachialgia: a prospective and randomized clinical trial. Int J Rehabil Res (2008) 1.00
Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2008) 0.99
Intertemporal choice in Parkinson's disease. Mov Disord (2011) 0.99
Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neurosci (2012) 0.99
Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs (2010) 0.98
Tramadol, fentanyl and sufentanil but not morphine block voltage-operated sodium channels. Pain (2006) 0.98
Sonography of the median nerve in CMT1A, CMT2A, CMTX, and HNPP. Muscle Nerve (2013) 0.97
Control of kinetic properties of GluR2 flop AMPA-type channels: impact of R/G nuclear editing. Eur J Neurosci (2002) 0.97
Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci (2009) 0.96
Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegener Dis (2012) 0.96
Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures. J Neural Transm (Vienna) (2015) 0.95
On emotional conflict: interference resolution of happy and angry prosody reveals valence-specific effects. Cereb Cortex (2009) 0.95
Needle acupuncture in chronic poststroke leg spasticity. Arch Phys Med Rehabil (2004) 0.94
Kinetic analysis of the agonistic and blocking properties of pentobarbital on recombinant rat alpha(1)beta(2)gamma(2S) GABA(A) receptor channels. Eur J Pharmacol (2002) 0.94
Topical antiseptics for the treatment of sore throat block voltage-gated neuronal sodium channels in a local anaesthetic-like manner. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.93
Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock. Crit Care Med (2006) 0.93
Treatment of phantom limb pain with botulinum toxin type A. Pain Med (2009) 0.93
Retention and transferability of team resource management skills in anaesthetic emergencies: the long-term impact of a high-fidelity simulation-based course. Eur J Anaesthesiol (2009) 0.93
[N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging (2002) 0.92
Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis. Muscle Nerve (2011) 0.92
Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2010) 0.91
Whole brain-based computerized neuroimaging in ALS and other motor neuron disorders. Amyotroph Lateral Scler (2008) 0.91
The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-Beta glycine receptor function. Pharmacology (2009) 0.90
Selective and nonselective benzodiazepine agonists have different effects on motor cortex excitability. Muscle Nerve (2006) 0.90
Perception of emotional speech in Parkinson's disease. Mov Disord (2006) 0.89
Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion. Acta Neuropathol (2012) 0.89
Preferred mexiletine block of human sodium channels with IVS4 mutations and its pH-dependence. Pharmacogenet Genomics (2005) 0.89
Changes in resting-state brain networks in writer's cramp. Hum Brain Mapp (2011) 0.89
Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. Br J Pharmacol (2002) 0.88
Association of molecular markers with perihematomal edema and clinical outcome in intracerebral hemorrhage. Stroke (2013) 0.88
Chronic deep brain stimulation in patients with tardive dystonia without a history of major psychosis. Mov Disord (2010) 0.88
Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®. J Neural Transm (Vienna) (2014) 0.88
Disturbed egocentric space representation in cervical dystonia. Mov Disord (2005) 0.87
Decreased mRNA expression of PGC-1α and PGC-1α-regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS. J Neuropathol Exp Neurol (2012) 0.87
Structural brain abnormalities in cervical dystonia. BMC Neurosci (2013) 0.86
Cortical processing of swallowing in ALS patients with progressive dysphagia--a magnetoencephalographic study. PLoS One (2011) 0.86
Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology (2005) 0.86
Frequency and treatment of depressive symptoms in a Parkinson's disease registry. Parkinsonism Relat Disord (2008) 0.86
A transmembrane residue influences the interaction of propofol with the strychnine-sensitive glycine alpha1 and alpha1beta receptor. Anesth Analg (2008) 0.85
Educational campaign on stroke in an urban population in Northern Germany: influence on public stroke awareness and knowledge. Int J Stroke (2012) 0.85
Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve (2013) 0.85
Temporal feature perception in cochlear implant users. PLoS One (2012) 0.85
Resuscitation from septic shock with capillary leakage: hydroxyethyl starch (130 kd), but not Ringer's solution maintains plasma volume and systemic oxygenation. Shock (2004) 0.85
Emotional speech in Parkinson's disease. Mov Disord (2008) 0.85
Negative- versus positive-pressure ventilation in intubated patients with acute respiratory distress syndrome. Crit Care (2012) 0.85
Central white matter degeneration in bulbar- and limb-onset amyotrophic lateral sclerosis. J Neurol (2014) 0.85
In vivo myograph measurement of muscle contraction at optimal length. Biomed Eng Online (2007) 0.85
Changes of emotional prosody in Parkinson's disease. J Neurol Sci (2009) 0.84
Role of mitochondria in kainate-induced fast Ca2+ transients in cultured spinal motor neurons. Cell Calcium (2007) 0.84
Mechanisms of cold sensitivity of paramyotonia congenita mutation R1448H and overlap syndrome mutation M1360V. J Physiol (2003) 0.84
Ca++/CaMKII switches nociceptor-sensitizing stimuli into desensitizing stimuli. J Neurochem (2012) 0.83
Brain-derived neurotrophic factor and exercise in fibromyalgia syndrome patients: a mini review. Rheumatol Int (2011) 0.83
Value of quantitative analysis of routine clinical MRI sequences in ALS. Amyotroph Lateral Scler (2011) 0.83
Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol (2012) 0.83
Decreased brain activation to tongue movements in amyotrophic lateral sclerosis with bulbar involvement but not Kennedy syndrome. J Neurol (2009) 0.83